Our Work in
For more than 80 years, Merck has contributed to the discovery and development of novel medicines and vaccines to combat infectious disease. Today, Merck is a global leader in antimicrobials with a proud heritage, broad portfolio and innovative pipeline.
Merck's Research Laboratories played a central role in the development of antimicrobials
Merck, in collaboration with Rutgers University, developed one of the first methods for mass production of penicillin
Merck markets a number of antibacterial, antifungal, and antiviral products and vaccines for the treatment or prevention of infectious diseases in markets around the globe
We're not done yet. We need to maintain our commitment and our interest and continue to bring our full capability set to trying to do more to help solve the problem of infectious disease.”
Maintaining active R&D programs to address unmet medical needs in the prevention and treatment of infectious disease
Monitoring trends in antibacterial resistance as exemplified by our longstanding commitment to surveillance studies
Supporting responsible use of antimicrobials to help slow development of resistance and preserve current therapeutic options
Advocating for improvements in regulatory guidance and financial incentives to support and accelerate innovation in the development of new antimicrobials, vaccines, services and solutions
There is a critical need for solutions to manage the growing problem of antimicrobial resistance.
Research and innovation will lead to the development of new antibiotics.
Antimicrobial stewardship promotes the appropriate use of antimicrobials to reduce resistance.
Policies can help spur innovation and regulate the use of antibiotics.
In addition to our own antimicrobial research efforts, Merck also works with scientists across the world.
Through its Merck Innovation Network (MINt), the company actively collaborates with leading scientists in the antimicrobial field to investigate novel therapeutic targets, evaluate new pathways for drug targeting and develop novel tools and technologies. Merck has a number of ongoing collaborations with scientists at universities including Harvard, Yale and Princeton.
Nicole Mahoney, director, Global Regulatory Policy, Merck, on how antimicrobial resistance is forcing policy makers to rethink the way diseases are managed, from how infections are diagnosed and tracked to how anti-infectives are developed and used.LEARN MORE